← Back to Search

Neuromodulation

Transcranial Magnetic Stimulator for Postpartum Depression

N/A
Waitlist Available
Led By Alexander McGirr, MD PhD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Women currently experiencing peripartum depression as determined by the MINI-International Neuropsychiatric Interview
Refuse antidepressant therapy, or have depression that has not improved with psychotropics and/or psychotherapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up administered at baseline, halfway (week 2) and after rtms treatment (week 4). all participants will complete the qids-sr at 8 weeks postpartum.
Awards & highlights

Study Summary

This trial will help to establish whether or not rTMS is an effective treatment for peripartum depression.

Eligible Conditions
  • Postpartum Depression

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Women who are currently going through post-birth depression as determined by a special interview.
Select...
You don't want to take medication for depression, or you have tried medication and therapy but your depression hasn't gotten better.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~if the participant is postnatal, the scale will be administered at baseline and after rtms treatment (week 4). all participants will complete the mpas at 8 weeks postpartum.
This trial's timeline: 3 weeks for screening, Varies for treatment, and if the participant is postnatal, the scale will be administered at baseline and after rtms treatment (week 4). all participants will complete the mpas at 8 weeks postpartum. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Montgomery-Asberg Depression Rating Scale (MADRS) scores
Secondary outcome measures
Epithelial Attachment
Anxiety Symptoms
Perinatal Anxiety Symptoms
+4 more
Other outcome measures
Incidence of Treatment-Emergent Adverse Events
Side Effects
Toronto Side Effects Scale (1 week) (TSES)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open label iTBS rTMSExperimental Treatment1 Intervention
Participants will receive repetitive transcranial magnetic stimulation (rTMS) as a treatment for depression
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulator
2019
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
780 Previous Clinical Trials
841,723 Total Patients Enrolled
2 Trials studying Postpartum Depression
420 Patients Enrolled for Postpartum Depression
Alexander McGirr, MD PhDPrincipal InvestigatorUniversity of Calgary
4 Previous Clinical Trials
122 Total Patients Enrolled

Media Library

rTMS (Neuromodulation) Clinical Trial Eligibility Overview. Trial Name: NCT03949465 — N/A
Postpartum Depression Research Study Groups: Open label iTBS rTMS
Postpartum Depression Clinical Trial 2023: rTMS Highlights & Side Effects. Trial Name: NCT03949465 — N/A
rTMS (Neuromodulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03949465 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there currently any opportunities to join this experiment?

"Affirmative. Information on clinicaltrials.gov suggests that this medical study is currently seeking participants, which began advertising on December 1st 2022 and was most recently updated November 9th of the same year. A total of 30 patients are needed to be recruited from one location."

Answered by AI

Is the patient demographic for this clinical trial limited to those under 50 years old?

"As per the guidelines of this medical trial, potential participants must be aged 18 to 40."

Answered by AI

What qualifications are necessary for someone to be eligible for this research trial?

"This medical trial seeks 30 participants with postpartum depression aged 18 to 40. To qualify for the study, subjects must have a current MINI-International Neuropsychiatric Interview diagnosis of peripartum depression and exhibit moderate severity as indicated by an Edinburgh Postnatal Depression Scale score of 15 or greater (antepartum) or 12 or more (postpartum). Additional eligibility requirements include being pregnant within one month post childbirth, refraining from antidepressant therapy/not responding to psychotropic drugs or talk therapies, agreeing to remain on a stable medication plan throughout the study's duration, and falling between 18 and 40 years old."

Answered by AI

What is the sample size for this clinical exploration?

"Affirmative, the clinical trial is still searching for participants. The initial listing was posted on December 1st 2022 and has since been updated as of November 9th 2022. There are 30 slots available at a single site."

Answered by AI
~0 spots leftby Mar 2025